Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

The Effect of Aprepitant Regimen on the Prevention of High-Dose Cisplatin-Induced Nausea and Vomiting

Aprepitant Regimen의 고용량 Cisplatin 유발 오심 및 구토 예방 효과

  • Park, Su-Jin (Department of Pharmacy Service, Samsung Medical Center) ;
  • Choi, Ji-Seon (Department of Pharmacy Service, Samsung Medical Center) ;
  • Ahn, Jin-Seok (Department of Hematology and Oncology, Samsung Medical Center) ;
  • Shin, Ka-Young (Department of Pharmacy Service, Samsung Medical Center) ;
  • Min, Kyoung-A (Department of Pharmacy Service, Samsung Medical Center) ;
  • Chung, Seon-Young (Department of Pharmacy Service, Samsung Medical Center) ;
  • In, Yong-Won (Department of Pharmacy Service, Samsung Medical Center) ;
  • Sohn, Kie-Ho (Department of Pharmacy Service, Samsung Medical Center)
  • Received : 2010.03.01
  • Accepted : 2010.05.18
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Aprepitant is a substance P/neurokinin-1 (NK1)-receptor antagonist that was approved in 2003 for prevention of CINV. In addition, updated anti-emetic guidelines that include the aprepitant regimen have been published by NCCN and ASCO. However there is scarce clinical data in Korea. The prospective study was performed to evaluate the prevention of high dose cisplatin induced nausea and vomiting in all patients who started high-dose cisplatin-based chemotherapy at our hospital. We checked the nausea severity and vomiting episodes by calling patients within 4 to 5 days after chemotherapy. The retrospective study was performed to compare the prevention of CINV in solid tumor patients who switched their anti-emesis regimen from the standard regimen to the aprepitant regimen. In aprepitant regimen, aprepitant was added to the same anti-emetic regimen used during previous cycles. We checked the nausea, vomiting grades and adverse events in electronic medical records (EMR). In prospective study, 195 patients were included in the analysis. 88.2% of patients achieved a complete response (no emesis and no rescue therapy). In retrospective study, 54 patients were reviewed. With aprepitant regimen, nausea and vomiting grades were improved in 22 patients (40.7%) and in 9 patients (16.7%), respectively. Compared with standard regimen, addition of aprepitant provided superior prevention against CINV in Korean patients receiving highly emetogenic cisplatin-based chemotherapy. Moreover, aprepitant significantly prevented CINV in patients who received the standard regimen to prevent CINV in previous chemotherapy cycles.

Keywords

References

  1. Naeim A, Dy SM, Lorenz KA, et al., Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol, 2008; 26(23): 3901-3910.
  2. 김용범 Cisplatin을 포함한 항암화학요법 치료 시 환자에서 발생하는 오심 및 구토에서의 정맥주사용 및 경구용 Tropisetron과 Ondansetron의 비교연구. 대한산부회지, 1998; 41(10): 2544-2550.
  3. Poli BS, Rodrigues PJ, Carides AD, et al., Aprepitant protocol 054 study group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting, cancer, 2003; 97(12): 3090-3098. https://doi.org/10.1002/cncr.11433
  4. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med, 2008; 358: 2482-2494. https://doi.org/10.1056/NEJMra0706547
  5. Lohr L. Chemotherapy-induced nausea and vomiting. The Cancer Journal, 2008; 14(2): 85-93. https://doi.org/10.1097/PPO.0b013e31816a0f07
  6. Hesketh PJ, Kris MG, Grunberg SM, et al., Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol, 1997; 15: 103-109. https://doi.org/10.1200/JCO.1997.15.1.103
  7. F. Roila. Prevention of chemotherapy-and radiotherapyinduced emesis: Results of the Perugia consensus conference antiemetic subcommittee of the multinational association of supportive care in cancer (MASCC). Annals of Oncology, 1998; 9: 811-819. https://doi.org/10.1023/A:1008471812316
  8. Hesketh PJ. New treatment options for chemotherapyinduced nausea and vomiting. Support Care Cancer, 2004; 12: 550-554.
  9. Hesketh PJ, Grunberg SM, Gralla RJ, et al., The Oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group J Clin Oncol, 2003: 21; 4112- 4119. https://doi.org/10.1200/JCO.2003.01.095
  10. Andrews PL, Sanger GJ. Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction, Curr Opin Pharmacol 2002; 2: 650-656. https://doi.org/10.1016/S1471-4892(02)00227-8
  11. Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities, Curr Opin Investig Drugs, 2008; 9(7): 774-785.
  12. Van Belle SJ, Cocquvt V. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opin Pharmacother, 2008; 9(18): 3261-3270. https://doi.org/10.1517/14656560802548463
  13. National comprehensive cancer network clinical practice guideline in oncology TM; Antiemesis V.3., 2008.
  14. Kris MG, Hesketh PJ, Somerfield MR, et al., American society of clinical oncology guideline for antiemetics in oncology: Update J Clin Oncol, 2006; 24(18): 2932-2947. https://doi.org/10.1200/JCO.2006.06.9591
  15. Gralla RJ, Osoba D, Kris MG, et al., Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol, 1999; 16: 1174-1178.
  16. Majumdar AK, Howard L, Goldberg MR et al., Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of Clinical Pharmacology, 2006; 6: 291-230.
  17. McCrea JB, Majumdar AK, Goldberg MR, et al., Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 2003; 74: 17-24. https://doi.org/10.1016/S0009-9236(03)00066-3
  18. Massaro AM, Lenz KL. Aprepitant, a novel antiemetic for chemotherapy -induced nausea and vomiting. Ann Pharmacother, 2005; 39: 77-85. https://doi.org/10.1345/aph.1E242
  19. Oechsle K, Müller MR, Hartmann JT, et al., Aprepitant as salvage therapy in patients with chemotherapy -induced nausea and emesis refractory to prophylaxis with 5- HT3 antagonists and dexamethasone. Onkologie, 2006; 29: 557-561. https://doi.org/10.1159/000096689
  20. Gan TJ, Apfel CC, Kovac A, et al., A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg, 2007; 104: 1082-1089. https://doi.org/10.1213/01.ane.0000263277.35140.a3
  21. Jenns K. Importance of nausea. Cancer Nurs, 1994; 17(6): 488-493.
  22. Van Belle S, Lichinitser MR, Navari RM, et al., Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer, 2002; 94: 3032-3041. https://doi.org/10.1002/cncr.10516
  23. Warr DG. Chemotherapy-and cancer-related nausea and vomiting. Current Oncology, 2008; 15(1): S4-S9. https://doi.org/10.3747/co.2008.194